MedTrace Logo

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

NCT03789006 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-01-03

No results posted yet for this study

Summary

Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.

Conditions

  • Kidney Transplant Rejection

Interventions

DRUG

Antithymocyte Immunoglobulin (Rabbit)

Induction agent for living donor kidney transplantation

DRUG

Interleukin 2 Receptor Antagonist

Induction agent for living donor kidney transplantation

Sponsors & Collaborators

  • National Center for Kidney Diseases and Surgery

    collaborator UNKNOWN

  • University of Khartoum

    lead OTHER

Principal Investigators

  • Sarra Elamin, MD · Consultant Nephrologist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-21
Primary Completion
2022-03-21
Completion
2024-03-21

Countries

  • Sudan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03789006 on ClinicalTrials.gov